California is home to a robust pharmaceuticals industry that plays a significant role in global healthcare innovation. The sector comprises diverse companies, ranging from startups to large entities, developing medications and therapies to address various health conditions. These firms are engaged in areas like oncology, immunology, and chronic disease management, illuminating the path towards advanced treatment options. The rapid evolution of technology and increasing investment in biotechnology are propelling the industry forward, promising a future filled with groundbreaking therapies tailored to patient needs. California continues to be a hotspot for research and development, fostering a thriving ecosystem.

The pharmaceuticals companies listed here represent a spectrum of sizes, from small startups to large corporations, headquartered across California. With founding years stretching from the early 1990s to recent startups in 2018, these firms display varied specializations including cancer therapies, autoimmune treatments, and responsive healthcare solutions. They operate out of major cities such as San Diego, San Francisco, and Long Beach, contributing to local economies and the healthcare sector at large. Their innovations address significant medical needs, showcasing the practical impacts of their products.

Read on to discover the top pharmaceuticals companies in California.

Top 23 Pharmaceuticals Companies in California

1. Myovant Sciences

• Website: myovant.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 95%, Other 5%
• Latest funding: $1.7B, October 2022
• Founded year: 2016
• Headcount: 501-1000
• LinkedIn: myovant-sciences

Myovant Sciences is a pharmaceutical company based in Brisbane, California, that specializes in developing innovative treatments for various health conditions, particularly in women's health, oncology, and psychiatry. Founded in 2016, the company has quickly positioned itself as a player in the pharmaceutical industry, focusing on areas where there are significant unmet medical needs. Myovant's product pipeline includes therapies that aim to improve patient outcomes and enhance quality of life. The company has garnered attention for its commitment to research and development, evidenced by its recent funding of $1.7 billion in October 2022, which underscores its potential for growth and innovation in the healthcare sector. Myovant Sciences operates primarily in the United States, with a workforce that is largely concentrated in the country, reflecting its focus on the North American market.

2. Amplyx, now a subsidiary of Pfizer Inc.

• Website: amplyx.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: April 2021
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: amplyx-pharmaceuticals-inc

Amplyx, now a subsidiary of Pfizer Inc., is based in San Diego, California. Founded in 2006, the company focuses on developing innovative therapies for serious infections, particularly those caused by resistant pathogens. As part of Pfizer, Amplyx benefits from the extensive resources and research capabilities of its parent company, which is known for its commitment to advancing healthcare through scientific innovation. Amplyx's work is particularly relevant in the context of rising antimicrobial resistance, as it aims to address unmet medical needs in the treatment of fungal infections and other serious conditions. The company has not reported any recent funding, indicating it operates within the framework of Pfizer's established financial structure.

3. Agensys, Inc.

• Website: astellas.us
• Ownership type: Private
• Headquarters: Santa Monica, California, United States (USA)
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: agensys

Agensys, Inc., based in Santa Monica, California, operates as a subsidiary of Astellas Pharma US, Inc. Founded in 1997, the company is dedicated to the development and marketing of pharmaceutical products that address critical health issues. Its primary focus areas include oncology, cardiology, and immunology, where it aims to enhance patient outcomes through innovative therapies. Agensys is involved in various stages of drug development, from research to clinical trials, and emphasizes collaboration with healthcare providers to ensure that its products meet the needs of patients. The company also provides resources to support patients and their caregivers, reflecting its commitment to patient-centric care. While there is no reported funding, Agensys continues to operate within a robust framework of Astellas, contributing to the broader pharmaceutical landscape.

4. Aimmune Therapeutics

• Website: aimmune.com
• Ownership type: Corporate
• Headquarters: Brisbane, California, United States (USA)
• Employee distribution: United States (USA) 81%, United Kingdom (UK) 10%, Switzerland 5%, Other 4%
• Latest funding: $2.6B, August 2020
• Founded year: 2011
• Headcount: 501-1000
• LinkedIn: aimmune-therapeutics

Aimmune Therapeutics, based in Brisbane, California, is a biopharmaceutical company founded in 2011. The company is dedicated to creating innovative therapies aimed at treating food allergies and related gastrointestinal and metabolic diseases. Aimmune's mission is to transform the lives of patients and their families by providing effective, science-driven treatments that help manage these conditions. The company has established a strong pipeline of candidates for food allergies, developed both in-house and through collaborations with prominent biotechnology firms. Aimmune is a subsidiary of Nestlé Health Science, which further supports its research and development efforts. In 2020, Aimmune secured significant funding amounting to $2.6 billion, underscoring investor confidence in its potential to deliver impactful therapies.

5. Prometheus Biosciences, Inc.

• Website: prometheusbiosciences.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $10.8B, April 2023
• Founded year: 1995
• Headcount: 51-200
• LinkedIn: prometheusbiosciences

Prometheus Biosciences, Inc. is a biotechnology firm based in San Diego, California, founded in 1995. The company is dedicated to developing precision medicines for patients suffering from autoimmune diseases, with a particular emphasis on inflammatory bowel disease (IBD). Prometheus is known for its innovative approach to drug development, utilizing advanced technologies to create targeted therapies that address unmet medical needs. Their pipeline includes several promising candidates that are currently undergoing clinical trials, showcasing their commitment to research and development. In April 2023, Prometheus secured substantial funding, amounting to $108 million, which underscores investor confidence in their potential to deliver effective treatments. This financial backing will likely support their ongoing clinical programs and further their mission to improve patient outcomes in the field of immunology.

6. Portola Pharmaceuticals

• Website: portola.com
• Ownership type: Corporate
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 93%, United Kingdom (UK) 7%
• Latest funding: $1.4B, May 2020
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: portola-pharmaceuticals

Portola Pharmaceuticals, founded in 2003 and based in South San Francisco, California, is a biopharmaceutical company dedicated to developing innovative therapies for patients with serious and rare diseases. The company primarily focuses on hematology, with a strong emphasis on addressing critical health needs through its product portfolio. Notable among their offerings is Andexxa, which is designed to reverse the effects of anticoagulants in patients experiencing uncontrolled bleeding. Portola is committed to advancing research and development, aiming to provide effective treatment options for patients who often have limited alternatives. The company has also received substantial funding, with a reported amount of $1.4 billion as of May 2020, indicating strong investor confidence in their mission and potential for growth.

7. VelosBio Inc.

• Website: velosbio.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Latest funding: $2.8B, November 2020
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: velosbioinc

VelosBio Inc. is a pharmaceutical company based in San Diego, California, founded in 2017. The company specializes in developing innovative therapies, particularly in the field of oncology. With a small workforce of around 27 employees, VelosBio is focused on addressing significant health challenges through research and clinical trials. The company has attracted considerable investment, securing $275 million in funding in November 2020, which underscores its potential in the competitive pharmaceutical landscape. VelosBio's commitment to advancing cancer treatment positions it as a noteworthy player in the industry, although its relatively recent establishment may affect its visibility and influence compared to more established firms.

8. Vivera Pharmaceuticals

• Website: viverapharmaceuticals.com
• Ownership type: Private
• Headquarters: Newport Beach, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $440.0M, November 2020
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: viverapharmaceuticals

Vivera Pharmaceuticals, Inc. is a biopharma and medtech company based in Newport Beach, California, founded in 2018. The company specializes in innovative therapies and medical devices, with a strong emphasis on improving health outcomes and addressing pain management issues. Vivera holds global exclusivity for the patented TABMELT sublingual drug delivery system, which is designed for pharmaceutical use, and has developed the ZICOH electronic dispensing device, showcasing their focus on advanced drug delivery technologies. Vivera operates multiple divisions, including technologies, biosciences, medical devices, and advanced diagnostics, which allows them to integrate their patented technology with manufacturing and distribution capabilities. Their commitment to research and development is evident in their ongoing efforts to create non-addictive treatment alternatives for pain management. Furthermore, Vivera's involvement in community support through their non-profit organization, Vivera Cares, highlights their dedication to making a positive impact on vulnerable populations. The company has also secured significant funding, with a reported amount of $440 million in late 2020, indicating strong investor interest and potential for future growth.

9. Alios BioPharma

• Website: aliosbiopharma.com
• Ownership type: Corporate
• Headquarters: South San Francisco, California, United States (USA)
• Latest funding: $1.8B, September 2014
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: alios-biopharma

Alios BioPharma is a pharmaceutical company based in South San Francisco, California, founded in 2006. It operates under the umbrella of Johnson & Johnson, focusing on the development of innovative medicines and treatments for serious health conditions. The company is involved in various therapeutic areas, including oncology, immunology, and neuroscience. Alios BioPharma aims to improve patient outcomes through its research and development efforts, contributing to the broader mission of Johnson & Johnson to provide access to quality healthcare. The company has received significant funding, with a notable amount of $1.75 billion reported in 2014, indicating strong investor confidence in its potential to deliver impactful medical solutions.

10. Qpex Biopharma

• Website: qpexbio.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $10.0M, May 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: qpex-biopharma-inc

Qpex Biopharma, based in San Diego, California, is a biopharmaceutical company established in 2018. The firm specializes in the development of innovative antibiotics aimed at combating antimicrobial resistance, a growing global health crisis. Their product pipeline includes OMNIvance®, ORAvance™, and QPX9003, which target serious infections caused by drug-resistant bacteria. Qpex collaborates with healthcare organizations to provide effective treatments for these challenging infections. The company has a strong focus on research and development, leveraging partnerships to enhance patient care. Recently, Qpex received a $10 million grant from BARDA to support its clinical development programs, underscoring its commitment to addressing urgent medical needs. In 2023, Qpex became a wholly-owned subsidiary of Shionogi Inc., further expanding its capabilities in the field of infectious diseases.

11. sanofi us

• Website: sanofi.us
• Ownership type: Private
• Headquarters: Irvine, California, United States (USA)
• Employee distribution: United States (USA) 87%, Brazil 3%, China 3%, Other 6%
• Founded year: 2004
• Headcount: 10001+
• LinkedIn: sanofi-us

Sanofi US, based in Irvine, California, is a prominent pharmaceutical company that specializes in creating and delivering innovative healthcare solutions. Founded in 2004, the company has grown to employ over 10,000 individuals, with a significant portion of its workforce based in the United States. Sanofi US focuses on a broad spectrum of health needs, offering prescription medications, vaccines, and consumer health products. Their product portfolio includes treatments for various conditions, such as immunology, neurology, oncology, and rare diseases. Sanofi is also committed to social impact, emphasizing patient advocacy and corporate social responsibility. The company actively engages in clinical trials and has a strong pipeline of products, showcasing its dedication to improving patient outcomes and advancing healthcare.

12. Otsuka America, Inc.

• Website: otsuka-america.com
• Ownership type: Private
• Headquarters: San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Founded year: 1921
• Headcount: 51-200
• LinkedIn: otsuka-america-inc.

Otsuka America, Inc. is a healthcare company based in San Francisco, California, with a history dating back to 1921. As a subsidiary of Otsuka Pharmaceutical Co., Ltd., it operates primarily in the pharmaceutical sector, but also engages in nutraceuticals and consumer markets. The company develops innovative products aimed at treating various health conditions, including those affecting the central nervous system, oncology, gastroenterology, and cardiovascular health. Otsuka America is dedicated to enhancing health and well-being through its offerings, which include vitamins, minerals, and supplements. Their commitment to patient support and community involvement further underscores their role in the healthcare landscape. With a workforce of around 140 employees, Otsuka America continues to contribute to the health sector by creating new products that address the needs of patients and consumers alike.

13. HUYABIO International

• Website: huyabio.com
• Ownership type: Private
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 72%, China 15%, Japan 6%, Other 8%
• Latest funding: Other (Debt), $48.0M, April 2015
• Founded year: 2004
• Headcount: 51-200
• LinkedIn: huya-bioscience-international

HUYABIO International, founded in 2004 and based in San Diego, California, is a biopharmaceutical company dedicated to advancing China's pharmaceutical innovations on a global scale. The company specializes in developing novel therapeutic compounds, with a strong focus on oncology and cardiovascular health. HUYABIO collaborates with various research institutions and pharmaceutical companies to identify and license promising pre-clinical and clinical stage compounds. This collaborative approach not only accelerates the development process but also aims to meet significant medical needs worldwide. HUYABIO's pipeline includes several noteworthy programs, such as HBI-8000, an innovative oncology drug, and HBI-3000, aimed at treating cardiac arrhythmias. The company has also secured funding, with a reported amount of $48 million in 2015, which supports its ongoing research and development efforts. With a workforce of around 109 employees and a presence in multiple countries, HUYABIO is positioned to make a meaningful impact in the pharmaceutical sector.

14. ShouTi

• Website: shoutipharma.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Latest funding: $100.0M, October 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: shouti

ShouTi, established in 2017 and based in South San Francisco, California, is a biopharmaceutical company dedicated to drug development and research. The company specializes in creating innovative oral therapies aimed at chronic diseases, addressing significant unmet clinical needs in healthcare. ShouTi employs advanced computational chemistry and structural biology techniques to design and develop medications that can substantially improve patient outcomes. Their research and development efforts are supported by a robust drug discovery platform that integrates cutting-edge technologies. As of October 2021, ShouTi raised $100 million in funding, reflecting strong investor interest and confidence in its mission to deliver effective treatments for chronic conditions. The company is actively engaged in developing therapies for cardiovascular, pulmonary, and metabolic diseases, positioning itself as a relevant player in the pharmaceutical industry.

15. EpicentRx, Inc.

• Website: epicentrx.com
• Ownership type: Venture Capital
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $500,000, July 2022
• Founded year: 2002
• Headcount: 11-50
• LinkedIn: epicentrx

EpicentRx, Inc. is a biotechnology firm based in San Diego, California, founded in 2002. The company specializes in developing novel therapies aimed at treating inflammatory diseases and cancer. Their product pipeline includes Nibrozetone (RRx-001), which is currently in Phase 3 trials, and AdAPT (AdAPT-001), an immune checkpoint-stimulating anticancer immunotherapy. EpicentRx is dedicated to addressing significant unmet medical needs, focusing on improving patient quality of life during treatment. The company has received funding, including a grant of $500,000 in July 2022, which supports their ongoing research and development efforts. Their innovative approaches and active participation in clinical trials highlight their commitment to advancing therapeutic options in the pharmaceutical industry.

16. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, based in Seal Beach, California, is a biotechnology firm focused on immunotherapy solutions for cancer. Founded in 1992, the company has carved out a niche in the treatment of advanced prostate cancer with its flagship product, Provenge (sipuleucel-T). This therapy is groundbreaking as it was the first FDA-approved treatment that harnesses the power of a patient's own immune cells to combat cancer. Since its approval in 2010, Provenge has been administered to nearly 40,000 men, demonstrating its impact on patient survival rates. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, supporting the development of innovative cancer therapies for other companies. This dual focus on both treatment and manufacturing positions Dendreon as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes through advanced medical solutions.

17. Dermavant Sciences, an Organon company

• Website: dermavant.com
• Ownership type: Corporate
• Headquarters: Long Beach, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2024
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: dermavant-sciences

Dermavant Sciences, a subsidiary of Organon, is a biopharmaceutical company based in Long Beach, California. Founded in 2016, the company is dedicated to developing and commercializing innovative therapeutics in the field of immuno-dermatology. Dermavant's primary focus is on addressing significant unmet medical needs associated with chronic skin conditions. Their flagship product, VTAMA cream (tapinarof), is a topical treatment that has received FDA approval for plaque psoriasis and is currently under review for atopic dermatitis. The company is actively engaged in clinical research and product development, aiming to provide effective solutions for patients suffering from these conditions. Dermavant's pipeline includes both late-stage and earlier development candidates, indicating a robust commitment to advancing dermatological therapies. With a workforce of approximately 264 employees, Dermavant is positioned to make a meaningful impact in the pharmaceutical industry, particularly in the dermatology segment.

18. Pharmacyclics, an AbbVie Company

• Website: pharmacyclics.com
• Ownership type: Corporate
• Headquarters: Sunnyvale, California, United States (USA)
• Employee distribution: United States (USA) 85%, Switzerland 7%, Other 8%
• Latest funding: $21.0B, March 2015
• Founded year: 1991
• Headcount: 1001-5000
• LinkedIn: pharmacyclics

Pharmacyclics, an AbbVie Company, is a pharmaceutical firm based in Sunnyvale, California, founded in 1991. The company specializes in creating innovative treatments for cancer and immune-mediated diseases. Their flagship product, ibrutinib, is a Bruton's tyrosine kinase inhibitor that has been pivotal in treating various forms of blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma. Pharmacyclics is dedicated to conducting extensive clinical trials, boasting one of the most comprehensive oncology development programs for a single molecule in the industry. They are committed to improving patient outcomes and quality of life through their research and development efforts, which include ongoing collaborations with healthcare professionals and organizations. The company operates primarily in the United States, with a small presence in Switzerland and other regions, reflecting a focused operational strategy. Their ethical commitment to compliance and transparency further underscores their role in the pharmaceutical industry.

19. Circle Pharma, Inc.

• Website: circlepharma.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, $90.0M, September 2024
• Founded year: 2012
• Headcount: 11-50
• LinkedIn: circle-pharma-inc-

Circle Pharma, Inc. is a biotechnology company based in South San Francisco, California, founded in 2012. The firm specializes in developing innovative cancer therapies through its proprietary macrocycle technology. This approach aims to create treatments that not only target cancer effectively but also enhance the overall patient experience by reducing side effects associated with traditional therapies. Circle Pharma's primary customers include healthcare providers and patients seeking advanced cancer care solutions. The company has recently raised $90 million in Series D funding, reflecting investor confidence in its mission and potential. Their research and development efforts are centered around their MXMO™ platform, which is designed to create macrocycles capable of reaching targets that conventional medications cannot. This focus on addressing unmet medical needs in cancer treatment underscores their relevance in the pharmaceutical sector.

20. Orexigen Therapeutics

• Website: orexigen.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $75.0M, April 2018
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: orexigen-therapeutics

Orexigen Therapeutics, now known as Currax Pharmaceuticals LLC, is a pharmaceutical company based in San Diego, California. Founded in 2002, Currax is dedicated to tackling two of the most pressing health issues in the United States: obesity and smoking cessation. The company distributes both branded and generic medications, with a portfolio that includes CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), and Treximet® (sumatriptan/naproxen sodium). Currax is actively involved in clinical trials aimed at improving treatment options and outcomes for patients. Their recent initiatives, such as disease awareness campaigns, reflect their commitment to enhancing patient care. With a workforce of around 51-200 employees, Currax is positioned to make a significant impact in the pharmaceutical industry, particularly in the areas of weight management and smoking cessation. The company has also secured substantial funding, indicating ongoing support for its operations and growth.

21. Kite Pharma

• Website: kitepharma.com
• Ownership type: Corporate
• Headquarters: Santa Monica, California, United States (USA)
• Employee distribution: United States (USA) 65%, Netherlands 28%, United Kingdom (UK) 2%, Other 5%
• Latest funding: $11.9B, August 2017
• Founded year: 2009
• Headcount: 1001-5000
• LinkedIn: kite-pharma-inc-

Kite Pharma, Inc. is a biotechnology firm based in Santa Monica, California, founded in 2009. The company is dedicated to developing innovative cancer immunotherapy products, with a particular emphasis on CAR T-cell therapies. Kite Pharma aims to harness the immune system's power to treat various blood cancers, providing new hope for patients and healthcare providers alike. Their commitment to research and development is evident in their extensive pipeline, which includes therapies for hematological malignancies and ongoing clinical trials. Kite's acquisition by Gilead Sciences in 2017 has enhanced its operational capabilities, allowing for accelerated advancements in their therapeutic offerings. Kite Pharma operates with a focus on ensuring access to advanced therapies, reflecting their mission to transform cancer treatment.

22. Respira Therapeutics, Inc.

• Website: respiratherapeutics.com
• Ownership type: Corporate
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, November 2015
• Founded year: 2010
• Headcount: 1-10
• LinkedIn: respira-therapeutics-inc-

Respira Therapeutics, Inc., based in Palo Alto, California, is a biotechnology firm established in 2010. The company specializes in creating innovative inhalation therapies aimed at treating respiratory diseases, with a particular emphasis on pulmonary arterial hypertension (PAH). Their flagship product, RT234, is designed for as-needed use, offering a novel approach compared to traditional chronic treatment regimens. Respira employs advanced particle engineering and proprietary inhalation device technologies to enhance drug delivery to the lung periphery. The company is currently conducting Phase 2 clinical trials to validate the efficacy and safety of RT234, which has received FDA Orphan Drug designation. With a small team of dedicated professionals, Respira is focused on addressing significant unmet needs in the treatment of pulmonary diseases, aiming to improve patient outcomes through their innovative therapies.

23. pH Pharma Inc.

• Website: ph-pharma.com
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Latest funding: January 2018
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: ph-pharma-co.-ltd.

pH Pharma Inc., based in Palo Alto, California, is a biotechnology firm established in 2015. The company is dedicated to developing innovative healthcare products aimed at addressing unmet clinical needs. Their primary focus areas include drug development for conditions such as glaucoma and non-alcoholic steatohepatitis (NASH). pH Pharma operates both research and manufacturing facilities, targeting healthcare providers and patients who require effective treatments. The company has made strides in clinical research, notably with their candidate drug Sovesudil, which is currently in advanced clinical trials for glaucoma. They have also engaged in collaborations and licensing agreements to enhance their research capabilities and expand their product offerings. With a small team of 11-50 employees, pH Pharma is leveraging its global network to foster innovation in the pharmaceutical landscape.

Pharmaceuticals Insights: Key Companies in California

Want to Find More Pharmaceuticals Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!